Prioritizing CRO Spending Through a High-Inflation, Sparse-Funding Period

Atlas Venture reports in its 2022 Year in Review, there are "7000 drugs in clinical development around the world, supported by $200B of R&D spend".  With R&D being the lifeline of many biopharma companies, companies are feeling the pressure to get more done with capital already raised against a backdrop of a volatile economic environment and uncertain capital market.  What strategies are companies deploying to keep foundational R&D progressing?  How are executive teams managing CROs?  Are there opportunities for CROs to demonstrate better alignment with the rising costs and a tougher funding environment challenging biopharma companies?